NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT) today announced that on February 5, 2009, it had received a Nasdaq Staff Notification of Deficiency and Compliance Letter indicating that the Company had violated the shareholder approval rules under Nasdaq Marketplace Rule 4350(i)(1)(D)(ii) (the “Rule”) in connection with its sale during November and December of 2008 of units consisting of an aggregate of 1,662,500 common shares and warrants to acquire 1,662,500 common shares and an option to purchase additional units consisting of 886,667 shares and warrants to acquire 886,667 shares.
